MRC Technology, UCB and the University of Leicester have formed a new research consortium aimed at identifying new opportunities for drug discovery through the use of antibodies in structure-based drug discovery and design.   The consortium will use antibodies to identify and characterize novel regulatory or allosteric sites on therapeutic target proteins, to stabilize functionally of important protein conformational states, and to characterize key structural features of complexes formed with ...